WHAT IS KNOWN AND OBJECTIVE: The current pharmacotherapeutic treatment of major depressive disorder (MDD) generally takes weeks to be effective. As the molecular action of these drugs is immediate, the mechanistic basis for this lag is unclear. A drug that has a more rapid onset of action would be a major therapeutic advance and also be a useful comparator to provide valuable mechanistic insight into the disorder and its treatment. COMMENT: Recent evidence suggests that ketamine produces rapid-onset antidepressant action. Important questions are as follows: is it specific or coincidental to other effects; is there a dose-response relationship; and is the mechanism related to that of current antidepressants. NMDA receptor antagonism is unlikely the explanation for ketamine's antidepressant action. WHAT IS NEW AND CONCLUSION: It is not an exaggeration to state that the new findings, if validated, might produce a revolution in understanding and treating depressive disorders.
WHAT IS KNOWN AND OBJECTIVE: The current pharmacotherapeutic treatment of major depressive disorder (MDD) generally takes weeks to be effective. As the molecular action of these drugs is immediate, the mechanistic basis for this lag is unclear. A drug that has a more rapid onset of action would be a major therapeutic advance and also be a useful comparator to provide valuable mechanistic insight into the disorder and its treatment. COMMENT: Recent evidence suggests that ketamine produces rapid-onset antidepressant action. Important questions are as follows: is it specific or coincidental to other effects; is there a dose-response relationship; and is the mechanism related to that of current antidepressants. NMDA receptor antagonism is unlikely the explanation for ketamine's antidepressant action. WHAT IS NEW AND CONCLUSION: It is not an exaggeration to state that the new findings, if validated, might produce a revolution in understanding and treating depressive disorders.
Authors: Julia Zaccarelli-Magalhães; André Rinaldi Fukushima; Natalia Moreira; Marianna Manes; Gabriel Ramos de Abreu; Esther Lopes Ricci; Paula A Faria Waziry; Helenice de Souza Spinosa Journal: Pharmacol Rep Date: 2019-12-20 Impact factor: 3.024
Authors: Maryam Ardalan; Betina Elfving; Ali H Rafati; Monireh Mansouri; Carlos A Zarate; Aleksander A Mathe; Gregers Wegener Journal: Eur Neuropsychopharmacol Date: 2020-01-20 Impact factor: 4.600
Authors: Bashkim Kadriu; Maximillian Greenwald; Ioline D Henter; Jessica R Gilbert; Christoph Kraus; Lawrence T Park; Carlos A Zarate Journal: Int J Neuropsychopharmacol Date: 2021-01-20 Impact factor: 5.176
Authors: Juan Francisco Rodríguez-Landa; Jonathan Cueto-Escobedo; Luis Ángel Flores-Aguilar; Gilberto Uriel Rosas-Sánchez; María de Jesús Rovirosa-Hernández; Francisco García-Orduña; Miguel Carro-Juárez Journal: J Evid Based Integr Med Date: 2018 Jan-Dec